Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · October 12, 2022

Trametinib Plus Dabrafenib in Patients With Unresectable or Distant Metastatic BRAF V600–Mutant Melanoma

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
Eur. J. Cancer 2022 Sep 25;175(2022)254-262, C Dutriaux, C Robert, JJ Grob, L Mortier, O Dereure, C Lebbe, S Mansard, F Grange, EM Neidhardt, T Lesimple, L Machet, C Bedane, H Maillard, S Dalac-Rat, C Nardin, A Szenik, A Denden, P Saiag

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading